Bayer AG (XSWX:BAYN) Accumulated Depreciation: CHF0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BAYN Bayer AG XSWX:BAYN
52 GF Score
Price CHF44.18
GF Value CHF24.68
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bayer AG Accumulated Depreciation?

Bayer AG XSWX:BAYN 52 Accumulated Depreciation is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 52/100 and a GF Value™ of CHF24.68 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Bayer AG's quarterly accumulated depreciation increased from Sep. 2025 (CHF0 Mil) to Dec. 2025 (CHF-16,011 Mil) but then stayed the same from Dec. 2025 (CHF-16,011 Mil) to Mar. 2026 (CHF0 Mil).

Bayer AG's annual accumulated depreciation increased from Dec. 2023 (CHF-15,029 Mil) to Dec. 2024 (CHF-16,587 Mil) but then stayed the same from Dec. 2024 (CHF-16,587 Mil) to Dec. 2025 (CHF-16,011 Mil).

Bayer AG Accumulated Depreciation Related Terms

Bayer AG Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Bayer AG's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Accumulated Depreciation Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14,049.15 -14,470.39 -15,028.85 -16,586.56 -16,010.79

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -16,010.79 0.00
XSWX:BAYN
52GF Score
Bayer AG XSWX:BAYN
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of CHF0 Mil mean?
Bayer AG (XSWX:BAYN) has a Accumulated Depreciation of CHF0 Mil as of Mar. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Bayer AG and its competitors.
Is Bayer AG's Accumulated Depreciation too high?
Bayer AG's current Accumulated Depreciation is CHF0 Mil. Overall, Bayer AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Accumulated Depreciation compare to LLY and JNJ?
Bayer AG's Accumulated Depreciation of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Drug Manufacturers company?
A good Accumulated Depreciation depends on the Drug Manufacturers industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Bayer AG and its competitors. Bayer AG's current Accumulated Depreciation is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.68, compared to a current price of CHF44.18 — trading 79% above its estimated fair value. The current Accumulated Depreciation is CHF0 Mil. Bayer AG's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Accumulated Depreciation is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF44.18 is trading 79% above its estimated GF Value™ of CHF24.68. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Accumulated Depreciation: CHF0 Mil
  • GF Value™: CHF24.68 vs. price of CHF44.18 (79% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
52GF Score

Get the complete analysis for XSWX:BAYN

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF44.18
Price
CHF24.68
GF Value